NVAX
Novavax Inc
11.20$
-0.9%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 60.8% | 63.6% | 53.7% | 66.2% | 64.4% | 72.3% | 67.1% | 68.8% | 82.6% | 83.2% | 81.6% | 80.7% | |
| 39.3% | 31.6% | 35.5% | 37.4% | 33.5% | 34.0% | 20.4% | 19.0% | 22.7% | 20.5% | 21.9% | 20.0% | |
| 39.3% | 31.6% | 35.5% | 57.7% | 53.1% | 59.2% | 56.6% | 45.8% | 64.7% | 62.5% | 75.8% | 75.3% | |
| 7.5% | 16.5% | 1.6% | 1.8% | 5.5% | 6.9% | 3.4% | 16.9% | 2.9% | 9.0% | 2.2% | 2.0% | |
| 4.2% | 2.3% | 1.2% | 0.5% | 0.5% | 0.6% | 0.8% | 0.8% | 1.1% | 1.0% | 1.1% | 1.0% | |
| 29.7% | – | – | – | – | – | – | – | – | – | – | – | |
| 7.5% | 7.1% | 9.1% | 6.8% | 7.4% | 6.9% | 8.7% | 8.5% | 9.6% | 9.6% | 10.8% | 11.8% | |
| 140.9% | 139.9% | 164.1% | 123.7% | 130.7% | 140.0% | 105.9% | 97.2% | 113.3% | 110.9% | 113.9% | 120.0% | |
| 88.6% | 91.0% | 59.4% | 63.7% | 69.0% | 74.0% | 32.7% | 29.1% | 36.4% | 39.1% | 32.8% | 34.6% | |
| 0.1% | 0.3% | 0.5% | 0.5% | 0.6% | 0.4% | 0.4% | 0.4% | 0.4% | 0.2% | 0.2% | 0.4% | |
| 6.1% | 7.4% | 4.3% | 4.4% | 3.4% | 2.7% | 2.6% | 3.8% | 1.3% | 2.1% | 1.5% | 2.4% | |
| 10.1% | 9.3% | 12.4% | 9.3% | 9.9% | 10.9% | 13.2% | 12.8% | 20.7% | 20.8% | 27.9% | 30.5% | |
| -40.9% | -39.9% | -64.1% | -23.7% | -30.7% | -40.0% | -5.9% | 2.8% | -13.3% | -10.9% | -13.9% | -20.0% | |
| -280.2% | -268.2% | -367.1% | -264.3% | -287.7% | -321.0% | -347.2% | -328.0% | -388.7% | -388.3% | -438.8% | -484.6% | |
| 6.2% | 6.9% | 10.3% | 9.1% | 9.3% | 10.3% | 13.7% | 13.3% | 13.8% | 14.7% | 15.7% | 17.2% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.